The Frontiers of Organ Transplantation and Cell Therapy

  • Rafael Matesanz
Part of the Advances in Experimental Medicine and Biology book series (AEMB, volume 741)


The biggest problem in the area of organ transplantation is often the mismatch between supply and demand. Extrapolating the transplant waiting lists in Spain at the end of a year to the global population, more than one million people would be able to benefit from a transplant if there were enough available organs and adequate infrastructure. The first frontier and the most important is therefore the donation of organs. The aim of this chapter is to set out the most notable points concerning the various themes (donation, rejection, xenotrasnplants, tissue transplantation and stem cells therapy), and describe new avenues to be explored: The frontiers that it will be necessary to cross in order to continue the progress in saving lives and improving the health of hundreds of thousands of people across world.

In the last years, embryonic stem cells have become in the great hope of many millions of patients across the world. In theory, the possibility to have unlimited quantities of these cells, to culture them, and to make them differentiate into cells of the liver, nervous system or heart would in fact become the ideal solution for the treatment of millions of patients. It is quite plausible that what organ transplantation has represented in the 20th century, bringing down taboos and saving hundreds of thousands of lives, is going to be replaced by stem cell therapy in the 21st Century.


Stem Cell Transplantation Cell Therapy Organ Transplantation Organ Donation Brain Death 
These keywords were added by machine and not by the authors. This process is experimental and the keywords may be updated as the learning algorithm improves.


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 3.
    Murray JE, Merril JP, Harrison J. Renal Homotransplantation in identical twins. Surg Forum 1955; VI:432–436.Google Scholar
  2. 5.
    Matesanz R. Organ procurement in Spain. The Lancet 1992; 340:733.CrossRefGoogle Scholar
  3. 6.
    Matesanz R, Miranda B, Felipe C et al. Continuous improvement in organ donation. Transplantation 1996; 61:1119–1121.PubMedCrossRefGoogle Scholar
  4. 7.
    Matesanz R. Factors influencing the adaptation of the Spanish model of organ donation. Transplant International 2003; 16:736–741.PubMedCrossRefGoogle Scholar
  5. 8.
    Matesanz R, Gil B. Strategies to opitimize deceased organ donation. Transplantation Reviews 2007; 21:177–188.CrossRefGoogle Scholar
  6. 9.
    El modelo español de donación y trasplantes. In: Rafael Matesanz, ed. Aula Médica, Madrid, 2008.Google Scholar
  7. 10.
    Bozzi G, Matesanz R, Saviozzi A et al. Summary: the quality improvement program in organ donation of the Tuscany region. Transplant Proc 2004; 36:424–425.PubMedCrossRefGoogle Scholar
  8. 11.
    Sánchez-Fructuoso AI, Marques M, Prats D et al. Victims of cardiac arrest occurring outside the hospital: a source of transplantable kidneys. Ann Intern Med 2006; 145:157–164.PubMedGoogle Scholar
  9. 12.
    Kootstra G. The asystolic, or non-heartbeating, donor. Transplantation 1997; 63:917–921.PubMedCrossRefGoogle Scholar
  10. 13.
    Bernat JL, D’Alessandro Am, Port FK et al. Report of a national conference on donation after cardiac death. Am J Transplant 2006; 6:281–291.PubMedCrossRefGoogle Scholar
  11. 14.
    Gjertson DW. Look-up survival tables for living-donor renal transplants: OPTN/UNOS data 1995–2002. Clin Transpl 2003; 337–386.Google Scholar
  12. 15.
    The Consensus Statement of the Amsterdam Forum on the care of the living kidney donor. Transplantation 2004; 78:491–492.Google Scholar
  13. 16.
    Organ trafficking and transplant tourism and commercialism. The Declaration of Istambul. The Lancet 2008; 372:5–6.Google Scholar
  14. 17.
    Starzl TE. Immunosuppressive therapy and tolerance of organ allografts. N Engl J Med 2008; 358:407–411.PubMedCrossRefGoogle Scholar
  15. 18.
    Chatenoud L. The long and winding road towards induction of allograft tolerance in the clinic. Transplant International 2008; 21:725–727.PubMedCrossRefGoogle Scholar
  16. 19.
    Los Xenotrsplantes. In: Carlos Romeo Casabona and Jorge Guerra, ed. Comares, Granada, 2003.Google Scholar
  17. 20.
    Groth CG. Looking back. Heading forward. Xenotransplantation 2008; 15:1–2.PubMedCrossRefGoogle Scholar
  18. 21.
    Hellman, KB, Nerem RM. Advancing tissue engineering and regenerative medicine. Tissue Engineering 2007; 13:2823–2824.PubMedCrossRefGoogle Scholar
  19. 22.
    Chung S. Bladder tissue engineering: a new practical solution? The Lancet 2006; 367:1215–1218.CrossRefGoogle Scholar
  20. 23.
    Lanzetta M, Petruzzo P, Dubernard JM et al. Second report (1998–2006) of the international registry of hand and composite tissue transplantation. Transpl Immunol 2007; 18:1–6.PubMedCrossRefGoogle Scholar
  21. 24.
    El milagro de los trasplantes. De la donación de órganos a las células madre. In: Rafael Matesanz, ed. La Esfera de los Libros, Madrid, 2006.Google Scholar
  22. 25.
    Rocha, V, Labopin M, Sanz G et al. For the acute leukemia working party of european blood and marrow transplant group and the Eurocord-Netcord Registry. Transplants of umbilical-cord blood or bone marrow from unrelated donors in adults with acute leukemia. N Engl J Med 2004; 351:2276–2285.PubMedCrossRefGoogle Scholar

Copyright information

© Landes Bioscience and Springer Science+Business Media 2012

Authors and Affiliations

  • Rafael Matesanz
    • 1
  1. 1.National Transplant Organization (ONT) of SpainMadridSpain

Personalised recommendations